// App-Quantinova.ai

BSH19‐PO‐079 : Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)

Researchers

Presenter

  • A. McMillan

Principal Investigators

  • L. Sehn

  • A. Herrera

  • M. Matasar

  • M. Kamdar

  • S. Assouline

  • M. Hertzberg

  • T.M. Kim

  • W.S. Kim

  • M. Ozcan

  • J. Hirata

  • E. Penuel

  • J. Cheng

  • G. Ku

  • C. Flowers

Medical Centers

  • Division of Pathology, Nottingham University Hospitals, Nottingham, United Kingdom

  • BC Cancer Agency, Vancouver, BC, Canada

  • City of Hope, Duarte, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of NC, NC, United States

  • Montreal University, Montreal, QC, Canada

  • Prince of Wales Hospital, Sydney, Australia

  • Chonnam National University Hospital

  • Samsung Med Cntr, Korea, Republic of

  • Ankara University, Ankara, Turkey

  • Genentech Inc., San Francisco, United States

  • Roche, Mississauga, Canada

  • Winship Cancer Institute of Emory University,Atlanta, GA,Vereinigte Staaten

Locations

  • United Kingdom

  • Canada

  • United States

  • Australia

  • Turkey

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • B-cell lymphoma 2

  • cMYC

Drug/Treatment

  • Polatuzumab vedotin

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Cohort

Phase

  • I

Study Id's

  • NCT02257567

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved